gene transfer?
disease can be triggered. This subsequent lung disease is no longer interactive with CFTR activity nor with mucus In 1989, the association between Cftr (the gene) and cystic fibrosis or CF (the disease) was first reported. Since then, Cl − concentration or fluidity and its kinetics is independent of the CFTR and common to all CF patients. more than 500 mutations in Cftr have been identified. CFTR (the Cftr product) has been well characterised and
The border between the CF disease and the lung disease has been named as the point of no-return (PNR). Arrival shown to be involved in cAMP-dependent transmembrane Cl − transport. Subsequently, several mouse Cftr at the PNR is presumably preceded by a number of cycles of bacterial proliferation/inflammation, after colonisation knock-outs have been obtained and shown to lead to a deficiency in epithelial cell Cl − transport. Transfer of Cftr of the lung has occurred. 1 The time that a CF lung can resist before reaching the PNR, in other words, the time into either CFTR-deficient or CFTR-mutant cells both in vitro and in vivo has been shown to restore a normal that the CF disease lasts, depends on genetic factors, like the CFTR-dependent rheological and bactericidal proper-CFTR-dependent Cl − transport. Moreover, a number of clinical studies have shown that gene transfer of wildties of the luminal mucus and on the health care (antibiotics, DNase, isolation, etc) provided to the patient. type human CFTR cDNA into the airways of CF patients leads to the transient restoration of the Cl − transport funcThe more active the CFTR and/or better the health care:
(1) the better the control on mucus fluidity and bacterition and/or the transmembrane potential difference across the airway epithelium. cidal activity; (2) the higher the first line of defence against bacterial colonisation/proliferation; and then (3) The accumulated knowledge undoubtedly proves that mutations in Cftr are the genetic cause of CF. However, the longer the duration of the CF disease preceding the lung disease. this fact has been extended to the assumption that Cftr (and therefore CFTR) is interactive with CF along the In non-CF individuals, wild-type CFTR activity prevents bacterial colonisation of the lung; thus, the PNR is course of the disease; although no evidence has been shown so far in support of such an assumption. The difnever reached and the lung disease is not triggered. Although mild mutations like A455E can significantly ference between 'being the cause of' and 'being interactive with' refers to the duration of the functional interdelay arrival of the PNR, mutant CFTR (including A455E) cannot avoid the lung reaching the PNR nor progressing action between the elements in play, namely CFTR and CF. Although mutated CFTR causes CF, it does not prove into and through the lung disease. Therefore, the role of the CFTR is limited to avoiding that a lasting interaction exists between CFTR and CF; in other words, that the persistence and progression of the or delaying the arrival of the PNR, where the lung disease can be triggered. As the CF disease but not the lung disease disease need to be continually caused by a reduced CFTR activity. We suggest that the mutant CFTR causes a priis interactive with CFTR activity, any rational therapeutic attempts to manage the disease by manipulating CFTR mary lung dysfunction which in turn leads to a different pathological setting, no longer interactive with the CFTR activity should be restricted to the CF disease stage. Thus, clinically effective CFTR gene transfer must be exclusactivity and characterised by an autonomous kinetics.
Recent epidemiological evidence shows that the kinively before the PNR.
The lung disease represents a terminal phase in the CF etics of progression of lung CF is directly related to the reduced activity of CFTR (at least for the ⌬F508 and the patient's lifespan. However, the PNR is not close to death. According to the epidemiological data, the com-A455E mutations) up to a point where further progression of the phenotype is independent of the CFTR mon rate of death for lung disease CF patients is rn = 15% per year; putting the PNR roughly around at least 6-7 activity (or the mutation on the Cftr).
1-4 Based on our data, which indicate that the CFTR would be noninteryears before death. 1 The 6-7-year span of the lung disease covers greater than 50% of the life span (approximately active throughout the course of the disease it causes, we postulate a new model describing the course of CF.
10-12 years age) of Latin-American and a 20-30% of the life span of European/North American CF patients. The According to our model, lung CF would be composed of two separate disorders: CF disease followed by lung disprobability of a CF patient of dying within 6 years can be predicted by the score NIH. 5 Score NIH values lower ease; which, although causally related, are not of the same nature and interact with different factors. CF disease is than 70 correspond to probabilities (of dying within 6 years) higher than 0.33. This means that 33% of the CF characterised by a physiopathological setting in the lung which is caused, and interactively maintained, by the patients scoring less than 70, are close to their respective PNR. According to this, in gene therapy clinical trials of them phase I studies. However, according to the proposed model, these studies have not been focused on the where patients with relatively high scores NIH (Ͼ70) are included, up to 33% of them are beyond their respective right window. The formal difference between a severe ⌬F508-like and PNR. That is, for 1/3 of the patients included, CFTR gene transfer does not have any rational support. a mild A455E-like lung CF pathway is the time needed for reaching the PNR. Beyond the PNR both kinetics are The concept of PNR has been derived from epidemiological evidence. 1 As its biological nature has not been the same. 1, 3 Therefore, for a young presymtomatic CF lung, a delay in the PNR would mimic the difference characterised, a precise definition of the border between CF disease and lung disease based on clinical data is so far between developing a severe CF phenotype (like ⌬F508) or developing a mild CF phenotype (like A455E). At the not possible. As the decision of whether a given patient has already passed over the PNR is not straightforward, limit, if the PNR were sufficiently delayed, the CF lung might behave like a non-CF healthy carrier lung. Preventhen, inclusion criteria for recruitment of patients into clinical trials cannot be clearly derived. A clear-cut defitive CFTR gene transfer before the onset of the first clinical symptoms thus appears to be the ideal way to delay nition of the PNR, the point beyond which Cftr gene transfer is no longer meaningful, in biological and clinical the PNR and the arrival of the lung disease. According to the preceding discussion, development of terms is mandatory for an adequate selection of the patients entering clinical trials and for a rational theraa successful gene therapy approach to CF should radically switch from the current strategy, which is peutic approach to the disease.
Apart from the clinical aspects, the preceding disaddressed to the therapeutic reversion of the already installed disease, into the early preventive intervention cussion opens critical questions about regulatory issues concerning current gene therapy approaches to CF. The aimed at delaying the arrival of the PNR and to the lung disease. Preventive gene transfer should be initiated as review process for gene therapy clinical protocols by the regulatory authorities in the USA and in Europe is early in life as possible. Optimally, it should be coupled to perinatal screening for the detection of genetically mainly based on the document known as: 'Points to Consider in the Design and Submission of Human Somatic-Cell determined, but still clinically unaffected, CF patients, in order to protect them from progressing into the CF disease Gene Therapy Protocols'. 6 Approval of a clinical protocol is contingent on the answer to the points: the first one and reaching the PNR. As far as CF preventive gene transfer is concerned, a ('objectives and rationale of the proposed research') asks: 'Why is the disease selected for treatment by means of lasting expression of the CFTR will be required. Such a lasting expression might be achieved either by integene therapy as a good candidate for such treatment?'. In other words, it must be possible to make predictions gration vectors delivered into airway epithelium progenitor cells or by repetitive applications of the (integrative on the potential effectiveness of the gene transfer on the basis of the accumulated knowledge of the disease and or not) vector delivered into already committed airway epithelium cells. The first alternative is not feasible with on the activity of the transferred gene. As the CFTR is noninteractive with the lung disease, Cftr is simply not the the current technology and knowledge and the second is limited to the use of highly nonimmunogenic vectors. candidate gene for attempting therapeutic gene transfer on lung disease patients. Therefore, as long as regulatory
Immunogenic vectors, like current adenovirus vectors, will probably be highly restricted if not completely issues are concerned, there is no rational frame to justify CFTR gene transfer into such a group of patients. The excluded from Cftr preventive gene transfer, whereas nonimmunogenic vectors, like for instance plasmid or restriction of future phase II gene therapy clinical protocols to CF disease patients and the exclusion of patients synthetic DNA, might gain relevance in the development of preventive gene transfer for CF. In this context, the who have reached the PNR and are undergoing the lung disease, should be ensured by the regulatory authorities efficiency of the vector might be resigned in favour of a lower immunogenicity. It has recently been shown that, in order to comply with the 'points to consider%' regulation.
in accordance with the flux control theory, a small percentage correction of the Cftr genetic defect can be Current phase I gene therapy clinical trials are mainly (although not exclusively) addressed to the immunoexpected to restore the normal Cl − transepithelium potential difference genotype over the complete airway epigenicity of the vector and the transferred gene product. Results from CF gene therapy phase I studies including thelium. Under the right equilibrium between the time a low efficiency vector keeps expressing the transferred lung disease patients, like most current studies, should be taken with much caution, if conclusions are to be extrapogene and the frequency of repeat applications of the same vector, a cumulative effect might be expected to occur: lated to the immunologically different CF disease. The lung disease is characterised by repetitive cycles of baceg sooner or later, the number of cells necessary to compensate for the whole airway epithelium, and able to terial proliferation/inflammation, with progressive lung tissue damage by immunomediators and immune cells.
cause effective prevention, should be reached. Currently, there is a conspicuous decline in the hope Lung disease patients do not provide the cleanest biological scenario for drawing conclusions about immunothat gene therapy will be able to provide a clinically effective alternative for CF in the near future. 
